Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in